LENZ
Commercializes VIZZ, an FDA-approved aceclidine eye drop for adult presbyopia.
$4.72
After-hours close−0.40 (−7.77%)
At close$5.12(+6.44%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.02 | — | — |
| Aug 2026 | −$1.05 | −$1.02 | +2.9% |
| May 2026 | −$1.10 | −$1.32 | −20.0% |
| Mar 2026 | −$0.91 | −$1.16 | −27.5% |
| Nov 2025 | −$0.67 | −$0.59 | +11.9% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$1.02 | — | — | $4.5M | — | — |
| Aug 11, 2026 | −$1.05 | −$1.02 | +2.9% | $2.4M | $5.5M | +130.8% |
| May 11, 2026 | −$1.10 | −$1.32 | −20.0% | $1.8M | $1.9M | +8.1% |
| Mar 24, 2026 | −$0.91 | −$1.16 | −27.5% | $3.1M | $1.6M | −48.5% |
| Nov 5, 2025 | −$0.67 | −$0.59 | +11.9% | $3.0M | $12.5M | +310.0% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Jul 30, 2025 | ||||||
| May 7, 2025 | ||||||
| Mar 19, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Jun 29, 2023 | ||||||
| Mar 30, 2023 | ||||||
| Dec 30, 2022 | ||||||
| Sep 29, 2022 | ||||||
| Jun 29, 2022 | ||||||
| Mar 30, 2022 | ||||||
| Dec 30, 2021 | ||||||
| Sep 29, 2021 | ||||||
| Jun 29, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||